All posts in Generally

Dear SMOB members,The FOPH has defined criteria for the recognition of medical obesity centers, which are now applied within the framework of “Spezialitätenliste / Liste des specialités” for the reimbursement of pharmacological treatments. The SMOB and SSED/ASEMO have expressed reservations regarding these criteria. In this context and with a view to contributing constructively, the SMOB […]

On behalf of our members, SMOB is sending an open letter to the BAG to draw attention to current problems with the implementation of the Wegovy® specialty list. The aim is to ensure medical care for patients with obesity.

Bernd Schultes1, Marco Bueter2,3, Lucie Favre4,5,6, Katharina Timper7,8 for the collaborative task force “prioritization of anti-obesity pharmacotherapy” of the Swiss Society for the Study of Morbid Obesity and Metabolic Disorders (SMOB) Background The current limited availability of the GLP-1 receptor agonist (GLP-1 RA) product Wegovy® (2.4 mg semaglutide) demands a prioritization by means of which […]

To our Patients,To the loved ones of people living with obesity,To our Colleagues in healthcare, Obesity care has seen considerable improvements in the past years. Pharmacotherapy and bariatric-metabolic surgery can now offer several treatment options that are secure and efficient.However, as it often happens when medical progress evolves fast, good practice recommendations and treatments with […]